10 completed, 7 terminated, 3 recruiting, 3 withdrawn. 14 Phase 2, 6 Phase 1, 4 Not applicable, 3 Early Phase 1.
Follow fluoromisonidazole: new trials by email Literature Review of fluoromisonidazole trials Research Report on fluoromisonidazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose Escalation Using Hypoxia-adjusted Radiotherapy DE-HyART, Standard Arm, Cisplatin injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 124 | 2024-04-08 | 2025-01-17 |
| Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), 18F-fluoromisonidazole - Head and Neck Squamous Cell Carcinoma, Brain Metastases | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 48 | 2023-05-17 | 2024-09-23 |
| BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma | Early Phase 1 | Completed | Emory University | 9 | 2022-04-28 | 2025-03-13 |
| Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma 18F-FMISO PET, 18F-FLT PET - Glioma | Phase 1 | Suspended | Weill Medical College of Cornell University | 8 | 2021-02-01 | 2026-01-27 |
| Feasibility of FMISO in Brain Tumors ¹⁸F-Fluoromisonidazole, Computed Tomography, Magnetic Resonance Imaging - IDH Wild Type Glioblastoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 77 | 2019-06-01 | 2026-09-18 |
| FMISO PET/CT Imaging Trial for Assessing Hypoxia in Soft Tissue Sarcomas 18F-FMISO - Soft Tissue Sarcoma | Phase 1 | Terminated | University of Pennsylvania | 5 | 2019-02-01 | 2021-03-18 |
| Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment [18F]fluoromisonidazole, Bevacizumab, positron emission tomography (PET/CT). - Recurrent Glioblastoma | Phase 1 | Terminated | Abramson Cancer Center at Penn Medicine | 2 | 2018-04-18 | 2020-02-17 |
| Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging FMISO - Hepatocellular Carcinoma | Phase 2 | Terminated | University of Alabama at Birmingham | 3 | 2017-10-30 | 2021-02-21 |
| [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer 18F-Fluoromisonidazole, Arterial Embolization, Computed Tomography - Adult Liver Carcinoma, Liver Cirrhosis | Phase 2 | Completed | Stanford University | 5 | 2016-09-13 | 2024-01-31 |
| A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 122 | 2016-08-31 | 2026-09-25 |
| Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization [18F] FMISO - Liver Cancer, Liver Neoplasm | Phase 2 | Completed | National Institutes of Health Clinical Center (CC) | 3 | 2015-06-12 | 2019-04-23 |
| Biomarker Correlates of Hypoxia in Metastatic Melanoma Pimonidazole hydrochloride (Hypoxyprobe™-1), Optional 18F-FMISO PET scan (18F-fluoromisonidazole), Surgical Resection of Melanoma Metastases - Melanoma, Skin Cancer | Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2014-10-01 | 2016-05-09 | |
| Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients 18F-FMISO, PET/CT - Non-Small-Cell-Lung Cancer (NSCLC) | Not applicable | Completed | Memorial Sloan Kettering Cancer Center | 25 | 2013-12-16 | 2025-04-30 |
| Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy 18F-MISO - Squamous Cell Carcinoma of the Head and Neck | Early Phase 1 | Withdrawn | University of Arkansas | 2013-12-01 | 2021-08-19 | |
| FMISO-PET in Brain Tumors and SCS Effect 18F-FMISO, PET without SCS, SCS - Malignant Glioma | Phase 2 | Terminated | Bernardino Clavo, MD, PhD | 6 | 2013-06-01 | 2018-08-24 |
| Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water [18F]fluoro-2-deoxy-D-glucose (FDG), 1H-1-(3-[18F]-fluoro-2-hydroxy-propyl)-2-nitro-imidazole [18F]-fluoromisonidazole, [15O]water - Brain Cancer | Phase 1 | Terminated | University of Utah | 2 | 2013-03-27 | 2024-10-01 |
| Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer 18F-Fluoromisonidazole, Carboplatin, Computed Tomography - Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 138 | 2012-02-22 | 2026-04-21 |
| 18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma fludeoxyglucose F 18, 18F-fluoromisonidazole, positron emission tomography - Recurrent Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2010-02-01 | 2017-11-17 |
| MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme FMISO, MRI, PET - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 50 | 2009-08-24 | 2019-04-08 |
| Clinical Evaluation of the New Hypoxia Imaging Agent HX4 [F-18] FMISO, [F-18] HX4 - Head and Neck Cancer, Lung Cancer | Phase 1 / Phase 2 | Completed | Siemens Molecular Imaging | 12 | 2009-06-01 | 2012-09-25 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Hepatocellular (4) · Glioblastoma (4) · Head and Neck Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Brain Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Glioma (3) · Lung Neoplasms (3) · Breast Neoplasms (2) · Liver Neoplasms (2) · Neoplasms (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Astrocytoma (1) · Carcinoma (1)
National Cancer Institute (NCI) (5) · Memorial Sloan Kettering Cancer Center (2) · Proacta, Incorporated (2) · Abramson Cancer Center at Penn Medicine (1) · Bernardino Clavo, MD, PhD (1) · Emory University (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · National Institutes of Health Clinical Center (CC) (1) · OHSU Knight Cancer Institute (1) · Rajiv Gandhi Cancer Institute & Research Center, India (1) · Siemens Molecular Imaging (1) · Stanford University (1) · University College London (UCL) Cancer Institute (1) · University of Alabama at Birmingham (1)
United States (21) · Canada (2) · China (1) · India (1) · New Zealand (1) · Spain (1) · United Kingdom (1)
Bernardino Clavo, MD, PhD (1) · Donald A Podoloff, M.D. (1) · Elizabeth Gerstner (1) · Elliot B Levy, M.D. (1) · Evan Osmundson, MD, PhD (1) · Francisco Robaina, MD, PhD (1) · Jacob Shin, MD (1) · Janet Eary (1) · Janis P O'Malley, M.D. (1) · Jeffrey Yap, PhD (1) · Jonathan Zager, M.D. (1) · Joseph Rajendran (1) · Joseph W Kim (1) · Juan C Alonso, MD, PhD (1)
PMID 16763816, PMID 17448882, PMID 17869020, PMID 27185374, PMID 27822900, PMID 28249612, PMID 29902200, PMID 35395276, PMID 35485937, PMID 39365957, PMID 40949474
2009 (1), N01CM37008 (1), N01CM370089 (1), P30CA124435 (1), P30CA138292 (1), R37CA288577 (1), U01CA080098 (1), U01CA157442 (1), U10CA021661 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186689 (1)